A comparison of the acute hemodynamic and delayed effects of 50% exchange transfusion with two different cross-linked hemoglobin based oxygen carrying solutions and Pentastarch

Artificial Cells, Blood Substitutes, and Biotechnology

Volumn 34, Issue 2, 2006, Pages 145-157

  Bonegio, Ramon G B ^a   Fuhro, Robert ^b   Ragno, Gina ^b   Valeri, C Robert ^b,d   Lieberthal, Wilfred ^c  

^a BOSTON MEDICAL CENTER   (United States)

^b Nav Blood Res Lab   (United States)

^c AMGEN INC   (United States)

^d Naval Blood Research Laboratory   (United States)

Author keywords

HBOC; Hemodynamic effects; Hemolink; Hemopure; Pentastarch; Renal function

Indexed keywords

BIODIVERSITY; CARDIOVASCULAR SYSTEM; HEMOGLOBIN; OXYGEN;

HBOC; HEMODYNAMIC EFFECTS; HEMOLINK; HEMOPURE; PENTASTARCH; RENAL FUNCTION;

HEMODYNAMICS;

HEMOGLOBIN; HETASTARCH; POLYMERIZED HEMOGLOBIN;

ARTICLE; BLOOD AUTOTRANSFUSION; CONTROLLED STUDY; CROSS LINKING; EXCHANGE BLOOD TRANSFUSION; GLOMERULUS FILTRATION RATE; HALF LIFE TIME; HEART OUTPUT; HEMATOCRIT; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINURIA; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; MEAN ARTERIAL PRESSURE; NONHUMAN; ONCOTIC PRESSURE; OXYGEN AFFINITY; RAT; SYSTEMIC VASCULAR RESISTANCE; URINE LEVEL; VASOCONSTRICTION; WEIGHT GAIN;

ANIMALS; BLOOD COMPONENT TRANSFUSION; BLOOD SUBSTITUTES; HEMATOCRIT; HEMODYNAMIC PROCESSES; HEMOGLOBINS; HETASTARCH; KIDNEY; PLASMA EXCHANGE; RAFFINOSE; RATS; RATS, INBRED STRAINS;

ANIMALIA; RODENTIA;

EID: 33644993269     PISSN: 10731199     EISSN: 15324184     Source Type: Journal    
DOI: 10.1080/10731190600580215     Document Type: Article

References (22)

1. Bunn, F., Alderson, P., Hawkins, V. (2001). Colloid solutions for fluid resuscitation. Cochrane Database Syst. Rev. CD001319.
2. Alderson, P., et al. (2004). Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst. Rev. CD001208.
3. Roberts, I., et al. (2004). Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst. Rev. CD000567.
4. Ernest, D., Belzberg, A.S., Dodek, P.M. (1999). Distribution of normal saline and 5% albumin infusions in septic patients. Crit. Care Med. 27: 46-50.
5. Roberts, J.S., Bratton, S.L. (1998). Colloid volume expanders. Problems, pitfalls and possibilities. Drugs 55: 621-630.
6. Lieberthal, W., et al. (2002). Comparison of the effects of a 50% exchange-transfusion with albumin, hetastarch, and modified hemoglobin solutions. Shock 17: 61-69.
7. Lieberthal, W., et al. (1999). o-raffinose cross-linking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin. J. Pharmacol. Exp. Ther. 288: 1278-1287.
8. Adamson, J.G., Moore, C. (1998). Hemolink, an o-raffinose crosslinked hemoglobin-based oxygen carrier, in Blood Substitutes: Principles, Methods, Products and Clinical Trials, T.M.S. Chang, Ed., Karger Landes: New York.
9. Gawryl, M., Clark, T., Rausch, C. (1991). Characterization of highly purified polymerized bovine hemoglobin, in Red Cell Substitutes: The Proceedings of the Second International Symposium of Red Cell Substitutes, S. Sekuguchi, Ed., Kindai Shuppan: Tokyo.
10. Lieberthal, W., Fuhro, R., Andry, C., Valeri, C. R. (2000). Effects of hemoglobin-based oxygen-carrying solutions in anesthetized rats with acute ischemic renal failure. J. Lab. Clin. Med. 135: 73-81.
11. Thompson, A., Valeri, C.R., Lieberthal, W. (1995). Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in rats. Am. J. Physiol. 269: H743-H748.
12. Lieberthal, W., Thompson, A., Valeri, C.R. (1996). Effects of nitric oxide inhibition on systemic and renal hemodynamics in the hemorrhaged rat. Kidney Blood Press Res. 19: 340-346.
13. Thompson, A., McGarry, A.E., Valeri, C.R., Lieberthal, W. (1994). Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: role of nitric oxide. J. Appl. Physiol. 77: 2348-2354.
14. Creteur, J., Vincent, J.L. (2003). Hemoglobin solutions. Crit Care Med 31: S698-S707.
15. Kingma, J.G., Jr., et al. (2002). The effects of hemodilution with Hemolink upon hemodynamics and blood flow distribution in anesthetized dogs. Artif. Cells Blood Substit. Immobil. Biotechnol. 30: 137-154.
16. Levy, J.H., et al. (2002). Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J. Thorac. Cardiovasc. Surg. 124: 35-42.
17. Moqattash, S., Lutton, J.D., Rosenthal, G., Abu-Hijleh, M.F., Abraham, N.G. (1997). Effect of blood substitute, recombinant hemoglobin, on in vivo hematopoietic recovery from AZT toxicity. Acta. Haematol. 98: 76-82.
18. Cheng, D.C. (2001). Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink) in cardiac surgery. Can. J. Anaesth. 48: S41-S48.
19. Lamy, M.L., et al. (2000). Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology 92: 646-656.
20. Sloan, E.P., et al. (1999). Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: A randomized controlled efficacy trial JAMA. 282: 1857-1864.
21. Kerner, T., et al. (2003). DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study. Intensive Care Med. 29: 378-385.
22. Swan, S.K., et al. (1995). Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Am. J. Kidney Dis. 26: 918-923.